subscribeSubscribe
Roche scrutinized by UK watchdog over `misleading` Rozlytrek promotional website

Roche scrutinized by UK watchdog over `misleading` Rozlytrek promotional website
Nicole DeFeudis ENDPTS
21 Sep 2023
Share Share
FoundationOne Liquid CDx Receives FDA Approval for entrectinib

FoundationOne Liquid CDx Receives FDA Approval for entrectinib
BUSINESSWIRE
04 Jan 2023
Share Share
Roche`s entrectinib gets FDA nod for Foundation Medicine`s companion diagnostic

Roche`s entrectinib gets FDA nod for Foundation Medicine`s companion diagnostic
Paul Schloesser ENDPTS
10 Jun 2022
Share Share
Chugai Obtains Approval of FoundationOne CDx Cancer Genomic Profile Rozlytrek

Chugai Obtains Approval of FoundationOne CDx Cancer Genomic Profile Rozlytrek
PRESS RELEASE
01 Oct 2020
Share Share
Roche’s Rozlytrek gets EC approval to treat solid tumours and NSCLC

Roche’s Rozlytrek gets EC approval to treat solid tumours and NSCLC
PHARMACEUTICAL-TECHNOLOGY
04 Aug 2020
Share Share
NICE to recommend Roche cancer treatment

NICE to recommend Roche cancer treatment
PHARMAFILE
26 Jun 2020
Share Share
NICE backs Rozlytrek for subset of NSCLC patients

NICE backs Rozlytrek for subset of NSCLC patients
Selina McKee PHARMATIMES
15 Jun 2020
Share Share
EMA committee recommends conditional marketing approval for Roche’s Rozlytrek

EMA committee recommends conditional marketing approval for Roche’s Rozlytrek
PHARMABIZ
30 May 2020
Share Share
Health Canada grants market authorization to ROZLYTREK® for ROS1-positive

Health Canada grants market authorization to ROZLYTREK® for ROS1-positive
BLOOMBERG
20 May 2020
Share Share
Health Canada approves Rozlytrek® for NTRK gene fusion-positive solid tumours

Health Canada approves Rozlytrek® for NTRK gene fusion-positive solid tumours
BLOOMBERG
28 Apr 2020
Share Share